Detailed TOC of Autoimmune Hemolytic Anemia Therapeutics Market by Product and Geography - Global Forecast & Analysis 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis
PART 04: MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
Market segmentation by product
Comparison by product
Corticosteroids - Market size and forecast 2018-2023
Monoclonal antibodies - Market size and forecast 2018-2023
Others - Market size and forecast 2018-2023
Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
Key leading countries
Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
Market drivers
Market challenges
PART 11: MARKET TRENDS
R&D of novel therapeutics
Advances in murine models
Development of combination therapies
PART 12: VENDOR LANDSCAPE
Overview
Landscape disruption
Competitive scenario
PART 13: VENDOR ANALYSIS
Vendors covered
Vendor classification
Market positioning of vendors
Amneal Pharmaceuticals Inc.
Baxter International Inc.
F. Hoffmann-La Roche Ltd.
Incyte Corp.
Kezar Life Sciences Inc.
Mylan NV
Pfizer Inc.
Rigel Pharmaceuticals Inc.
Sanofi
Teva Pharmaceutical Industries Ltd.
PART 14: APPENDIX
Research methodology
List of abbreviations
Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Corticosteroids - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Corticosteroids - Year-over-year growth 2019-2023 (%)
Exhibit 22: Monoclonal antibodies - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Monoclonal antibodies - Year-over-year growth 2019-2023 (%)
Exhibit 24: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Others - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by product
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Asia
Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in ROW
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: Amneal Pharmaceuticals Inc. - Vendor overview
Exhibit 51: Amneal Pharmaceuticals Inc. - Business segments
Exhibit 52: Amneal Pharmaceuticals Inc. - Organizational developments
Exhibit 53: Amneal Pharmaceuticals Inc. - Segment focus
Exhibit 54: Amneal Pharmaceuticals Inc. - Key offerings
Exhibit 55: Amneal Pharmaceuticals Inc. - Key customers
Exhibit 56: Baxter International Inc. - Vendor overview
Exhibit 57: Baxter International Inc. - Business segments
Exhibit 58: Baxter International Inc. - Organizational developments
Exhibit 59: Baxter International Inc. - Segment focus
Exhibit 60: Baxter International Inc. - Key offerings
Exhibit 61: Baxter International Inc. - Key customers
Exhibit 62: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 63: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 64: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 65: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 66: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 67: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 68: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 69: Incyte Corp. - Vendor overview
Exhibit 70: Incyte Corp. - Business segments
Exhibit 71: Incyte Corp. - Organizational developments
Exhibit 72: Incyte Corp. - Key offerings
Exhibit 73: Incyte Corp. - Key customers
Exhibit 74: Kezar Life Sciences Inc. - Vendor overview
Exhibit 75: Kezar Life Sciences Inc. - Business segments
Exhibit 76: Kezar Life Sciences Inc. - Organizational developments
Exhibit 77: Kezar Life Sciences Inc. - Key offerings
Exhibit 78: Kezar Life Sciences Inc. - Key customers
Exhibit 79: Mylan NV - Vendor overview
Exhibit 80: Mylan NV - Product segments
Exhibit 81: Mylan NV - Organizational developments
Exhibit 82: Mylan NV - Geographic focus
Exhibit 83: Mylan NV - Segment focus
Exhibit 84: Mylan NV - Key offerings
Exhibit 85: Mylan NV - Key customers
Exhibit 86: Pfizer Inc. - Vendor overview
Exhibit 87: Pfizer Inc. - Business segments
Exhibit 88: Pfizer Inc. - Organizational developments
Exhibit 89: Pfizer Inc. - Geographic focus
Exhibit 90: Pfizer Inc. - Segment focus
Exhibit 91: Pfizer Inc. - Key offerings
Exhibit 92: Pfizer Inc. - Key customers
Exhibit 93: Rigel Pharmaceuticals Inc. - Vendor overview
Exhibit 94: Rigel Pharmaceuticals Inc. - Business segments
Exhibit 95: Rigel Pharmaceuticals Inc. - Organizational developments
Exhibit 96: Rigel Pharmaceuticals Inc. - Key offerings
Exhibit 97: Rigel Pharmaceuticals Inc. - Key customers
Exhibit 98: Sanofi - Vendor overview
Exhibit 99: Sanofi - Business segments
Exhibit 100: Sanofi - Organizational developments
Exhibit 101: Sanofi - Geographic focus
Exhibit 102: Sanofi - Segment focus
Exhibit 103: Sanofi - Key offerings
Exhibit 104: Sanofi - Key customers
Exhibit 105: Teva Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 106: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 107: Teva Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 108: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibit 109: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 110: Teva Pharmaceutical Industries Ltd. - Key customers
Exhibit 111: Validation techniques employed for market sizing
Exhibit 112: Definition of market positioning of vendors
Keyplayers in Autoimmune Hemolytic Anemia Therapeutics Market by Product and Geography - Global Forecast & Analysis 2019-2023
Amneal Pharmaceuticals Inc.Baxter International Inc.
F. Hoffmann-La Roche Ltd.
Incyte Corp.
Kezar Life Sciences Inc.
Mylan NV
Pfizer Inc.
Rigel Pharmaceuticals Inc.
Sanofi
Teva Pharmaceutical Industries Ltd.